Medical News

RSS

ACF selects HCI, AAP to establish center of excellence for Head Start

Amid reports that an increasing number of Americans are living below the poverty level, UCLA/Johnson & Johnson Health Care Institute (HCI) is expanding its efforts to help low-income families.

18 Nov 2011

Research roundup: The effect of heart drug costs; Doctors' financial incentives when ordering stress tests

The researchers examined whether drug costs for heart attack patients affects health. Half of a group of more than 5,000 patients were given prescription coverage that eliminated co-payments and expanded drug choices. The others had "usual prescription coverage."

18 Nov 2011

Tikcro reports net loss of $1.0 million for third quarter 2011

Tikcro Technologies Ltd. today reported results for the third quarter and nine months ended September 30, 2011.

18 Nov 2011

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

The U.S. Food and Drug Administration today approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL.

18 Nov 2011

HealthStream prices public offering of 3,250,000 shares of common stock

HealthStream, Inc., announced today that it has priced a public offering of 3,250,000 shares of its common stock, consisting of 3,100,000 shares to be sold by the Company and 150,000 shares to be sold by certain selling shareholders at a price of $16.25 per share.

18 Nov 2011

FDA assigns new PDUFA date for Takeda's investigational type 2 diabetes therapy, alogliptin

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., today announced that the company received notification from the U.S. Food and Drug Administration (FDA) that its review of investigational type 2 diabetes therapy alogliptin, and thus the fixed-dose combination therapy alogliptin/pioglitazone, will be delayed.

18 Nov 2011

First Edition: November 18, 2011

In today's health policy headlines, reports indicate that the super committee continues to face difficulties and may not make its fast-approaching deadline.

18 Nov 2011

Tonix to initiate TNX-102 PK and BA study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.

18 Nov 2011

China Medical Technologies second quarter net revenues increase 18.1% to RMB238.5 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, announced its unaudited financial results for the second fiscal quarter ended September 30, 2011 ("2Q FY2011") today.

18 Nov 2011

HVTN debunks top 10 myths about HIV vaccine research

Dec. 1 is World AIDS Day, and in commemoration of the occasion, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, debunks the top 10 myths about HIV vaccine research.

18 Nov 2011

Pollution threatens health of Chinese population, UNEP report says

"The pollution that has accompanied China's spectacular rate of economic growth will have dire health consequences for its population, the United Nations has warned in a report," the International Business Times reports.

18 Nov 2011

Resistance of starved bacteria can be blocked

Many infections, even those caused by antibiotic-sensitive bacteria, resist treatment. This paradox has vexed physicians for decades, and makes some infections impossible to cure.

18 Nov 2011

Efforts to end AIDS could also reduce TB burden with proper funding

In response to Michael Gerson's November 11 column in which he said the end of AIDS is possible because of combination prevention and treatment innovations, David Bryden, the Stop TB advocacy officer at RESULTS, writes in a Washington Post letter to the editor, "Another benefit of [HIV] treatment is that it sharply reduces deaths from tuberculosis [TB], which is the primary killer of people living with HIV/AIDS."

18 Nov 2011